Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ta621

  1. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Technology appraisal guidance
    Published
    22 January 2020

  2. Past appeals and decisions

    Obesity (prolonged-release) - naltrexone-bupropion 12 December 2017 TA621 Osimertinib for untreated EGFR-positive non-small-cell lung...